The codevelopment of effective, safe anti–PD-1/PD-L1 agents with companion diagnostic assays faces significant challenges that could impede advancement of this therapeutic class if not properly addressed. Harmonization of current PD-L1 assays would standardize testing, provide guidelines for optimal PD-L1 evaluation, and may potentially circumvent this looming problem.